181 related articles for article (PubMed ID: 28324267)
1. Chemotherapy-induced irreversible alopecia in early breast cancer patients.
Kim GM; Kim S; Park HS; Kim JY; Nam S; Park S; Kim SI; Kim D; Sohn J
Breast Cancer Res Treat; 2017 Jun; 163(3):527-533. PubMed ID: 28324267
[TBL] [Abstract][Full Text] [Related]
2. Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer.
Rugo HS; Klein P; Melin SA; Hurvitz SA; Melisko ME; Moore A; Park G; Mitchel J; Bågeman E; D'Agostino RB; Ver Hoeve ES; Esserman L; Cigler T
JAMA; 2017 Feb; 317(6):606-614. PubMed ID: 28196257
[TBL] [Abstract][Full Text] [Related]
3. Prospective observational study of chemotherapy-induced alopecia after sequential FEC + taxane and the effects of age in breast cancer patients.
Fujii T; Ichiba K; Honda C; Tokuda S; Nakazawa Y; Ogino M; Kurozumi S; Obayashi S; Yajima R; Shirabe K
Breast Cancer; 2021 Mar; 28(2):329-334. PubMed ID: 32944881
[TBL] [Abstract][Full Text] [Related]
4. Permanent alopecia in patients with breast cancer after taxane chemotherapy and adjuvant hormonal therapy: Clinicopathologic findings in a cohort of 10 patients.
Fonia A; Cota C; Setterfield JF; Goldberg LJ; Fenton DA; Stefanato CM
J Am Acad Dermatol; 2017 May; 76(5):948-957. PubMed ID: 28284826
[TBL] [Abstract][Full Text] [Related]
5. Risk of treatment related death and febrile neutropaenia with taxane-based adjuvant chemotherapy for breast cancer in a middle income country outside a clinical trial setting.
Phua CE; Bustam AZ; Yusof MM; Saad M; Yip CH; Taib NA; Ng CH; Teh YC
Asian Pac J Cancer Prev; 2012; 13(9):4623-6. PubMed ID: 23167391
[TBL] [Abstract][Full Text] [Related]
6. Scalp cooling successfully prevents alopecia in breast cancer patients undergoing anthracycline/taxane-based chemotherapy.
Vasconcelos I; Wiesske A; Schoenegg W
Breast; 2018 Aug; 40():1-3. PubMed ID: 29660543
[TBL] [Abstract][Full Text] [Related]
7. Permanent hair loss associated with taxane chemotherapy use in breast cancer: A retrospective survey at two tertiary UK cancer centres.
Chan J; Adderley H; Alameddine M; Armstrong A; Arundell D; Fox R; Harries M; Lim J; Salih Z; Tetlow C; Wong H; Thorp N
Eur J Cancer Care (Engl); 2021 May; 30(3):e13395. PubMed ID: 33350015
[TBL] [Abstract][Full Text] [Related]
8. Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer: The SCALP Randomized Clinical Trial.
Nangia J; Wang T; Osborne C; Niravath P; Otte K; Papish S; Holmes F; Abraham J; Lacouture M; Courtright J; Paxman R; Rude M; Hilsenbeck S; Osborne CK; Rimawi M
JAMA; 2017 Feb; 317(6):596-605. PubMed ID: 28196254
[TBL] [Abstract][Full Text] [Related]
9. Registry study to assess hair loss prevention with the Penguin Cold Cap in breast cancer patients receiving chemotherapy.
Rice BA; Ver Hoeve ES; DeLuca AN; Esserman LJ; Rugo HS; Melisko ME
Breast Cancer Res Treat; 2018 Jan; 167(1):117-122. PubMed ID: 28921303
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Scalp Cooling in Preventing Chemotherapy-Induced Alopecia in Breast Cancer Patients Receiving Adjuvant Docetaxel and Cyclophosphamide Chemotherapy.
Cigler T; Isseroff D; Fiederlein B; Schneider S; Chuang E; Vahdat L; Moore A
Clin Breast Cancer; 2015 Oct; 15(5):332-4. PubMed ID: 25749072
[TBL] [Abstract][Full Text] [Related]
11. "Randomised controlled trial of scalp cooling for the prevention of chemotherapy induced alopecia".
Bajpai J; Kagwade S; Chandrasekharan A; Dandekar S; Kanan S; Kembhavi Y; Ghosh J; Banavali SD; Gupta S
Breast; 2020 Feb; 49():187-193. PubMed ID: 31865282
[TBL] [Abstract][Full Text] [Related]
12. Serum Biomarkers for Chemotherapy Cardiotoxicity Risk Detection of Breast Cancer Patients.
Hasan D; Ismail Y; Al Tibi A; Al-Zeidaneen SA; Odeh M; Burghel GJ; Natsheh I; Abdelnour A
Asian Pac J Cancer Prev; 2021 Oct; 22(10):3355-3363. PubMed ID: 34711013
[TBL] [Abstract][Full Text] [Related]
13. The effect of scalp cooling on CIA-related quality of life in breast cancer patients: a systematic review.
Marks DH; Okhovat JP; Hagigeorges D; Manatis-Lornell AJ; Isakoff SJ; Lacouture ME; Senna MM
Breast Cancer Res Treat; 2019 Jun; 175(2):267-276. PubMed ID: 30806923
[TBL] [Abstract][Full Text] [Related]
14. Scalp cooling has no place in the prevention of alopecia in adjuvant chemotherapy for breast cancer.
Tollenaar RA; Liefers GJ; Repelaer van Driel OJ; van de Velde CJ
Eur J Cancer; 1994; 30A(10):1448-53. PubMed ID: 7833100
[TBL] [Abstract][Full Text] [Related]
15. Permanent Chemotherapy-Induced Alopecia in Patients with Breast Cancer: A 3-Year Prospective Cohort Study.
Kang D; Kim IR; Choi EK; Im YH; Park YH; Ahn JS; Lee JE; Nam SJ; Lee HK; Park JH; Lee DY; Lacouture ME; Guallar E; Cho J
Oncologist; 2019 Mar; 24(3):414-420. PubMed ID: 30120165
[TBL] [Abstract][Full Text] [Related]
16. Decrease in breast density in the contralateral normal breast of patients receiving neoadjuvant chemotherapy: MR imaging evaluation.
Chen JH; Nie K; Bahri S; Hsu CC; Hsu FT; Shih HN; Lin M; Nalcioglu O; Su MY
Radiology; 2010 Apr; 255(1):44-52. PubMed ID: 20308443
[TBL] [Abstract][Full Text] [Related]
17. Hair Loss Prevention by a Scalp Cooling Device in Early Breast Cancer Patients: The Poliambulanza Preliminary Experience.
Prochilo T; Huscher A; Andreis F; Mirandola M; Zaina E; Pomentale B; Pedrali C; Zanotti L; Mutti S; Zaniboni A
Rev Recent Clin Trials; 2019; 14(1):66-71. PubMed ID: 30457055
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.
Mackey JR; Martin M; Pienkowski T; Rolski J; Guastalla JP; Sami A; Glaspy J; Juhos E; Wardley A; Fornander T; Hainsworth J; Coleman R; Modiano MR; Vinholes J; Pinter T; Rodríguez-Lescure A; Colwell B; Whitlock P; Provencher L; Laing K; Walde D; Price C; Hugh JC; Childs BH; Bassi K; Lindsay MA; Wilson V; Rupin M; Houé V; Vogel C;
Lancet Oncol; 2013 Jan; 14(1):72-80. PubMed ID: 23246022
[TBL] [Abstract][Full Text] [Related]
19. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15.
Fisher B; Brown AM; Dimitrov NV; Poisson R; Redmond C; Margolese RG; Bowman D; Wolmark N; Wickerham DL; Kardinal CG
J Clin Oncol; 1990 Sep; 8(9):1483-96. PubMed ID: 2202791
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase II adjuvant trial of dose-dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node-positive breast cancer.
Puhalla S; Mrozek E; Young D; Ottman S; McVey A; Kendra K; Merriman NJ; Knapp M; Patel T; Thompson ME; Maher JF; Moore TD; Shapiro CL
J Clin Oncol; 2008 Apr; 26(10):1691-7. PubMed ID: 18316792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
